“ADHD Drugmaker Unveils Bold Plan to Combat Chronic Shortage—Will It Be Enough?”
The Drug Enforcement Administration (DEA) has done something a tad unusual— they’ve just upped the production limit for Vyvanse, the ADHD medication from Takeda Pharmaceuticals, and its generic counterparts by about 24% to help tackle the pesky shortage that’s been plaguing the U.S. market. Now, while more focus might sound like a dream come true for some, one can’t help but wonder: are we really ready for a wave of hyper-focused individuals roaming the streets? Imagine it’s Collective Concentration Day and everyone’s laser-sharp… Could our society handle that level of productivity without the world descending into chaos? I mean, is it just me, or does this seem to skirt the fine line between helpful and downright shenanigans? What do you think?
The Drug Enforcement Administration increased the production limit for Takeda Pharmaceutical’s ADHD drug Vyvanse and its generic versions by about 24% to address the medicine’s ongoing shortage in the United States. What do you think?
“I don’t think the U.S. has the infrastructure to support that many focused people at once.”
Halee Browne, Gerbil Socializer
“I always knew the solution was more drugs.”
Tyler Gooden, Corporate Skeptic
“The DEA always knows where to get the good stuff.”
Jorge Reyes, Petroleum Sifter
The post ADHD Drugmaker To Ease Ongoing Shortage By Increasing Production appeared first on The Onion.
